<DOC>
	<DOC>NCT00332176</DOC>
	<brief_summary>The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1865 years of age, inclusive primary diagnosis of chronic HCV infection, genotype 1 Interferonbased treatmentnaïve Body Mass Index of 18 to 30, inclusive patients previously treated with Interferonbased therapy patients with diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Celgosivir</keyword>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Treatment-naive</keyword>
	<keyword>Early viral kinetics</keyword>
</DOC>